NCT04999488

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: AdventHealth Translational Research Institute · Academic / Other
• Sex: All
• Age: 65 Years – 90 Years
• Healthy volunteers: Accepted

Summary

This study is being done to gather data on whether oral supplementation of CoQ10 is enriched in the blood and muscles in older adults with sarcopenia. This study involves 28 consecutive days of oral CoQ10 supplementation to explore changes in muscle strength, aerobic capacity and physical function with CoQ10 supplementation.

Conditions

• Sarcopenia

Interventions

Type	Name	Description
DRUG	BPM31510	A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
OTHER	Placebo	A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.

Timeline

• Start date: 2023-12-01
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2021-08-10
• Last updated: 2023-07-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study